Insights & News / Life Sciences

September 8, 2022

Barnea: Representing Neve Pharma in Sale to Diplomat for NIS 81 Million

Neve Pharma is engaged in the development, marketing, and sale of nutritional supplements, as well as medical accessories in the ENT field. Sixty-five percent of the company was recently sold to the public company Diplomat for NIS 81 million. Neve Pharma was represented by Sagi Gross, Dor Levi-Tam, and Izabel Pashayev in the transaction.

See full article >

October 2, 2022

Barnea: Representing Pronto Diagnostics and Owners in Sale to Novolog

Sagi Gross and Dor Levi-Tam represented Pronto Diagnostics and its owners in a transaction to sell control of the company to Novolog. Pronto operates in the field of molecular genetic diagnostics.

See full article >

September 8, 2022

Barnea: Representing Naveh Pharma and Bigdam Ltd in Sale to Diplomat

The import giant Diplomat has acquired control of the companies Naveh Pharma and Bigdam Ltd for NIS 96 million. Advs. Sagi Gross, Dor Levi-Tam, and Izabel Pashayev successfully represented the companies and their owners in the transaction.

See full article >

May 22, 2022

BioGenCell Completes USD 16 Million Seed Round

Our firm represents BioGenCell, a stem cell research and development company located at Laniado Hospital. The company recently announced the completion of a USD 16 million seed round investment, aided by counsel from Advs. Itay Gura, Ido Freund, and Inbar Katzir. Our firm has represented the company since its inception.

See full article >

January 21, 2021

Dentsply Sirona Acquires Datum Dentel Ltd.

We represented Datum BioTech Ltd and its non-wholly owned subsidiary, Datum Dental Ltd, an Israeli company that develops medical devices for the mouth and jaw, in its sale to American company Dentsply Sirona. Advs. Micky Barnea and Ariella Dreyfuss advised the client throughout the deal.

See full article >

June 8, 2020

CardiacSense Signs USD 32M Deal to Sell Watches in India

Our firm serves as counsel for Cardiac Sense, a startup that developed a medical watch for remote patient vital signs monitoring and detection of fever and chronic diseases. We represent the startup in all legal matters. Recently, we assisted the company in an over USD 30 million agreement to supply medical watches for use in hospitals in India.

November 20, 2019

Podcast: Ariella Dreyfuss for 50inTech on Femtech

Ariella Dreyfuss talks to 50inTech in a special podcast about the growing femtech industry. She discusses challenges facing entrepreneurs in the field and offers advice on how to talk to investors.

See full article >

September 15, 2019

Barnea Represented CryoLife in a Strategic Transaction with the Israeli Medtech Startup Endospan

Our firm represented CryoLife in a strategic transaction with Israel-based endovascular stent graft system developer Endospan. The transaction involved an option to purchase Endospan for up to USD 450 million in the future, together with an exclusive distribution arrangement and USD 15 million in secured debt financing.

See full article >

July 16, 2019

Femtech Meetup at Barnea

Our firm hosted today a meetup for entrepreneurs in the femtech field. Co-hosting was 50inTech, a French organization that provides a platform for women in the high-tech industry. During the meetup, in which 25 entrepreneurs gathered, Ariella Dreyfuss delivered a brief overview of challenges, trends, and opportunities in the femtech field.

July 9, 2019

Femtech: The High-Tech Market Ignored and Then Discovered Was Worth Tens of Billions

Adv. Ariella Dreyfus, a partner in our firm who has advised startups in the femtech field, was interviewed by TheMarker for an article on the burgeoning femtech market. This market is estimated to reach a value of USD 50 billion in 2025.

See full article >

June 27, 2019

Barnea Represented Johnson & Johnson Innovation in an Investment Round in DayTwo

Our firm represented JJDC in its follow on investment in the Israeli medtech company DayTwo, as part of a $31 million series B round.

See full article >

June 3, 2019

Barnea Represented Johnson & Johnson Innovation in an Investment Round in Techsomed

Micky Barnea, Ariella Dreyfuss, Itay Gura, Mayer Winkler, and Ido Freund represented Johnson Johnson Innovation in an investment round in the Israeli medtech startup Techsomed Medical Technologies Ltd. Founded in 2012, Techsomed has developed an image analysis system that helps track tissue response to thermal ablation, the process of destroying tumors using extreme heat or cold. Techsomed intends to use the funding toward receiving regulatory approval in the US, Europe, and Japan. JJDC led the company's current round of financing, which included both former and new investors, such as Screen Holdings, the Alfred Mann Institute at the Technion (AMIT), NextLeap Ventures, and Axil Capital.

See full article >

May 26, 2019

Hosting a Delegation of German Medical Companies

Our firm hosted a delegation of German Companies, part of the Tech7 collaboration with SCE in the BIPA program (Bavarian Israeli Partnership Accelerator).

November 29, 2018

French Tech Tour – Healthcare Delegation

We hosted today a delegation of French startup companies from the life sciences and medtech sectors. The delegation was organized by the Embassy of France and visited Israel to learn about the local life sciences scene. During the event, Adv. Ariella Dreyfuss discussed the Israeli medtech ecosystem and the legal challenges companies should be aware of.

October 23, 2018

IBM Alpha Zone 8th Class Selection

Our firm participated in the selection process for the 8th class of the IBM Alpha Zone accelerator.

July 30, 2018

Barnea Represented JJDC as the Lead Investor in OrthoSpin Ltd.

Our firm represented the US pharmaceutical and medical devices company Johnson Johnson Development Corporation (JJDC) in a USD 3 million lead investment round in OrthoSpin Ltd. OrthoSpin is an Israeli-based startup that provides smart robotic external fixation systems.

See full article >

February 1, 2018

Barnea Advised on the $703 Million Acquisition of Theramex by CVC

Barnea Advised on the $703 Million Acquisition of Theramex by CVC Capital Partners. Theramex is Teva Pharmaceutical Industries' global women’s health portfolio.

See full article >

November 8, 2017

Hosting Australian Fund Bio Capital Impact

Barnea is hosting today Bio Capital Impact Fund, an Australian fund with vast experience in the BioTech, MedTech, and AgriTech industries. The representatives of the fund came to Israel to explore the possible investment in startups operating in those fields.

January 12, 2017

Hosting the South Carolina Business and Research Delegation

Barnea is hosting today a business and research delegation from South Carolina, comprised of business leaders, researchers and business developers at hospitals and research Institutions and economic development officials. They have come to Israel to promote collaboration with Israeli companies in Biomed, Cyber and Tech Automotive. Micky Barnea, our Managing Partner, will give a lecture on the legal aspects of doing business in Israel.

Together is empowering

Search by Practice

Insights & News / Life Sciences